National Cancer Institute
- Nanotechnology Characterization Laboratory (NCL), NCI
The NCL provides knowledge and services to help researchers transition nanomaterials-based cancer treatments from the laboratory into FDA-approved clinical trials. NCI, a component of the National Institutes of Health, established the Nanotechnology Characterization Laboratory to perform pre-clinical efficacy and toxicity testing of nanoparticles intended for cancer therapeutics or diagnostics. Information on participating in the NCL program is available on the NCI Website.